8-K: Silence Therapeutics Q3 2025: Divesiran Study Fully Enrolled

Silence Therapeutics announced its third quarter 2025 financial results, highlighted by the full enrollment of its SANRECO Phase 2 study for divesiran in polycythemia vera and a cash runway into 2028.

Summary

• Silence Therapeutics reported its financial results for the third quarter ended September 30, 2025, along with recent business highlights.
• The company completed enrollment in the SANRECO Phase 2 study of divesiran for the treatment of polycythemia vera (PV).
• Initial topline results from the SANRECO study are anticipated in the third quarter of 2026.
• Cash and cash equivalents, and short-term investments totaled $102.2 million as of September 30, 2025, providing a cash runway into 2028.
• Research & Development (R&D) expenses were $20.5 million for Q3 2025, a slight increase from $20.2 million in Q3 2024.
• General & Administrative (G&A) expenses decreased to $5.8 million for Q3 2025, down from $7.7 million in Q3 2024, primarily due to reduced reporting and compliance requirements and operating efficiencies.
• Net loss for Q3 2025 was $21.0 million, an improvement compared to a net loss of $35.5 million for Q3 2024, which was largely impacted by foreign currency loss.

Sentiment

Score: 7

Explanation: The company reported an improved net loss and reduced G&A expenses, alongside a strong cash position extending into 2028. The key operational highlight is the full enrollment of the SANRECO Phase 2 study for divesiran, with topline results expected in Q3 2026, indicating good progress in its clinical pipeline. While revenue declined, the focus is on R&D and clinical milestones for a clinical-stage company.

Positives

• Full enrollment achieved for the SANRECO Phase 2 study of divesiran for polycythemia vera (PV), a significant operational milestone.
• Initial topline results for the SANRECO study are anticipated in Q3 2026, providing a clear near-term catalyst.
• Strong cash position of $102.2 million as of September 30, 2025, which is expected to fund operational plans into 2028.
• Net loss significantly improved to $21.0 million in Q3 2025 from $35.5 million in Q3 2024.
• General & Administrative expenses decreased by $1.9 million to $5.8 million in Q3 2025, reflecting increased operating efficiencies and reduced reporting/compliance requirements.

Negatives

• Continued net operating losses, with a net loss of $21.0 million for Q3 2025 and $76.8 million for the nine months ended September 30, 2025.
• Revenue decreased significantly to $159 thousand for Q3 2025 from $1.498 million for Q3 2024.
• Revenue for the nine months ended September 30, 2025, was $525 thousand, down from $17.953 million in the same period of 2024.
• Cash and cash equivalents decreased to $82.031 million as of September 30, 2025, from $121.330 million as of December 31, 2024.

Risks

• History of net operating losses.
• Ability to obtain necessary capital to fund clinical programs.
• Early stages of clinical development of product candidates.
• Ability to obtain regulatory approval of and successfully commercialize product candidates.
• Potential undesirable side effects or other properties of product candidates.
• Reliance on third-party suppliers and manufacturers.
• Outcomes of any future collaboration agreements.
• Ability to adequately maintain intellectual property rights for product candidates.

Future Outlook

The company anticipates initial topline results from the SANRECO Phase 2 study of divesiran in polycythemia vera in the third quarter of 2026. Management expects to bring forward additional candidates from its mRNAi GOLD platform and advance its extra-hepatic work, with a strong finish to the year and meaningful pipeline catalysts ahead in 2026. The current cash position is expected to fund operational plans into 2028.

Management Comments

• "Silence continues to focus on operational execution, highlighted by the rapid achievement of full enrollment in our ongoing SANRECO Phase 2 study of divesiran, our first-in-class siRNA for PV." Craig Tooman, President and Chief Executive Officer.
• "We believe the positive momentum in our divesiran PV program, combined with exciting advancements in our early-stage pipeline, positions us well for both near and long-term value creation. We are looking forward to a strong finish to the year and meaningful pipeline catalysts ahead in 2026." Craig Tooman, President and Chief Executive Officer.
• "With a strong cash position providing a runway into 2028, we remain focused on executing to deliver topline Phase 2 data in PV next year, bringing forward additional candidates from our mRNAi GOLD platform where we see promising opportunities and advancing our extra-hepatic work." Rhonda Hellums, Chief Financial Officer.

Industry Context

Silence Therapeutics operates in the rapidly evolving biotechnology sector, specifically focusing on siRNA therapies. This technology aims to silence disease-associated genes, offering a precision medicine approach. The company's focus on polycythemia vera (PV), cardiovascular disease, hematology, and rare diseases aligns with areas of high unmet medical need, where gene-silencing therapies could offer significant advancements over traditional treatments. The successful enrollment of a Phase 2 study for a first-in-class siRNA for PV positions Silence as a notable player in developing novel treatments for hematological disorders.

Stakeholder Impact

• Shareholders: Positive impact due to strong cash runway into 2028, improved net loss, and significant progress in the lead clinical program (divesiran fully enrolled, topline data expected Q3 2026), potentially increasing long-term value.
• Employees: Focus on operational efficiencies might imply optimized resource allocation, but no direct impact on employment levels is stated.
• Patients/Medical Community: Potential for a new first-in-class siRNA therapy for polycythemia vera, addressing an unmet medical need.

Next Steps

• Deliver initial topline results from the SANRECO Phase 2 study of divesiran in Q3 2026.
• Bring forward additional candidates from the mRNAi GOLD platform.
• Advance extra-hepatic work.
• Achieve a strong finish to the year and meaningful pipeline catalysts in 2026.

Key Dates

Recommendation

The company demonstrates solid operational execution with the full enrollment of its lead Phase 2 study and a strong cash position. The improved net loss and reduced G&A are positive financial indicators for a clinical-stage biotech. However, the significant decline in revenue and continued overall net losses are factors to consider. The stock is likely to remain a "hold" until the topline Phase 2 data for divesiran is released in Q3 2026, which will be a critical catalyst for re-evaluation. The long cash runway provides stability, but the investment thesis hinges on successful clinical outcomes.

Keywords

siRNA, polycythemia vera, PV, divesiran, SANRECO, clinical trial, biotechnology, RNAi, hematology, rare diseases, drug development, financial results, Q3 2025